Newlink touts IDO safety in phase II interim results
By Randy Osborne
Staff Writer
Staff Writer
With clinical news pouring from pharma giants matching up the indoleamine 2,3-dioxygenase 1 (IDO1) blocker mechanism with PD-1 immune checkpoint inhibitors, Newlink Genetics Corp.'s interim results from NLG2103 seemed to take a back seat.
